Darwin Global Management: Stock Portfolio, Performance and Latest Trades
13F portfolio value
$3.8B
5 holdings at Q2 2026
Get an email when Darwin Global Management files a new 13F report
Free, no account needed. Unsubscribe with one click.
Darwin Global Management's portfolio
As of Q2 2026, filed August 14, 2026 · prices as of October 8, 2026
| Company | Share of portfolio | Average buy price | Return | Current price | Last quarter |
|---|---|---|---|---|---|
| 54.5% | $136.69 | +37.6% | $188.12 | Added +381% | |
Insmed Inc.INSM | 17.9% | $78.31 | +28.3% | $100.48 | Reduced −62% |
| 12.1% | $119.14 | +28.0% | $152.52 | Added +0.6% | |
Abivax Sa-AdrABVX | 9.26% | $89.72 | −0.7% | $89.05 | Added +4.4% |
| 6.23% | $25.69 | +33.2% | $34.21 | Reduced −0.7% |
Darwin Global Management's buys and sells
| Company | Action | Shares change | Value now |
|---|---|---|---|
Ambrx Biopharma Inc.641871108 | Sold out | −16,688,636 | — |
Vaxcyte Inc.PCVX | Added +374% | +2,170,845 | $187.9M |
Nuvalent Inc.670703107 | Added +2390% | +1,379,266 | $107.9M |
Biohaven Ltd.BHVN | New | +1,476,974 | $80.8M |
Alpine Immune Sciences Inc.02083G100 | New | +1,982,016 | $78.6M |
| New | +2,119,598 | $70M | |
| Sold out | −4,046,598 | — | |
| Sold out | −1,039,289 | — | |
Apogee Therapeutics Inc.03770N101 | New | +832,198 | $55.3M |
| Added +35% | +375,523 | $95.1M | |
| Sold out | −600,000 | — | |
Xencor Inc.XNCR | New | +1,109,650 | $24.6M |
| New | +473,200 | $17.9M | |
Elevation Oncology Inc.28623U101 | New | +2,332,928 | $12M |
| New | +465,000 | $10.6M | |
| New | +79,600 | $10.5M | |
Springworks Therapeutics Inc.85205L107 | Sold out | −192,734 | — |
Darwin Global Management's portfolio by sector
Share of the stock portfolio at Q2 2026.
| Sector | Share |
|---|---|
| Health Care | 100% |
Portfolio performance: Darwin Global Management vs. benchmarks
Your result if you had bought each reported portfolio on the day it was made public and held it until the next report, against the S&P 500 and Nasdaq-100.
- You, copying after each 13F filing – estimated value
- S&P 500
- Nasdaq-100
| Total return | Per year | |
|---|---|---|
| You, copying after each 13F filing – estimated value | −35.0% | −8.2% |
| S&P 500 | +89.0% | +13.6% |
| Nasdaq-100 | +113.3% | +16.4% |
Prices were available for 64% of the portfolio value on average; the rest is left out of the return.
Darwin Global Management's most traded stocks
Quarters with a buy or a sell, all reports since Q4 2020.
| Company | Quarters bought | Quarters sold |
|---|---|---|
| 8 | 6 | |
Insmed Inc.INSM | 7 | 2 |
Vaxcyte Inc.PCVX | 3 | 2 |
| 2 | 3 | |
Argenx SE - ADRARGX | 1 | 4 |
| 2 | 3 | |
| 4 | 1 | |
| 2 | 3 | |
Abivax Sa-AdrABVX | 4 | 0 |
| 3 | 1 | |
Geron Corp.GERN | 1 | 3 |
| 2 | 2 | |
| 2 | 2 | |
Immunovant Inc.IMVT | 1 | 3 |
| 3 | 1 |